Sort
23,748 grants matching “melanoma”
The B7x pathways in the tumor microenvironment
$399,000Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2025 · CA
DNA Markers As Surrogates:Melanoma Patient Response
$398,931Dave S B Hoon · Saint John'S Cancer Institute · R33 · FY2007 · CA
The B7x pathways in the tumor microenvironment
$398,901Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2021 · CA
DNA Markers As Surrogates:Melanoma Patient Response
$398,878Dave S B Hoon · Saint John'S Cancer Institute · R33 · FY2006 · CA
Highly stable mini-circRNA vaccine with maximally activated and long-lasting T cells for HPV-related cancer combination immunotherapy
$398,823Gordon Parry · Ampedrna Biosciences Llc · R43 · FY2024 · CA
Biomaterial Cancer Vaccines that Generate Patient-Specific Antigen In Situ
$398,803David J Mooney · Harvard University · R01 · FY2018 · CA
Endothelial plasticity in glioma vascularization and therapy resistance
$398,750Yi Fan · University Of Pennsylvania · R01 · FY2022 · NS
Bioengineering approaches to map mechanotransduction in the living cell
$398,750Ning Wang · Northeastern University · R01 · FY2023 · GM
Endothelial plasticity in glioma vascularization and therapy resistance
$398,750Yi Fan · University Of Pennsylvania · R01 · FY2023 · NS
Targeting Transcriptional Co-repressor CoREST Complex in Melanoma
$398,711Byungwoo Ryu · Hackensack University Medical Center · R01 · FY2020 · CA
Targeting Transcriptional Co-repressor CoREST Complex in Melanoma
$398,711Byungwoo Ryu · Hackensack University Medical Center · R01 · FY2021 · CA
Targeting Transcriptional Co-repressor CoREST Complex in Melanoma
$398,711Byungwoo Ryu · Hackensack University Medical Center · R01 · FY2018 · CA
Signaling importance of âfunctionlessâ lyso-PAF, an inactive form of platelet activating factor, in melanoma with mutant Nras
$398,657Jing Chen · University Of Chicago · R01 · FY2025 · CA
UV damage, repair, and mutagenesis
$398,608Gerd P Pfeifer · Beckman Research Institute/City Of Hope · R37 · FY2013 · ES
Focused kV X-ray Modulated Conformal Radiotherapy for Small Targets
$398,574Wu Liu · Stanford University · R01 · FY2022 · EB
Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy
$398,500Guizhi Zhu · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients
$398,444Stuart J Kahn · Syntrix Biosystems, Inc. · R44 · FY2018 · HL
Study of Hepatic Arterial Infusion of Melphalan for Malignancy in the liver
$398,395Marybeth Hughes · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
An In Situ Patient-specific Chemo-Immunotherapy for Skin Cancers
$398,375Louis D Falo · University Of Pittsburgh At Pittsburgh · P50 · FY2015 · CA
Molecular Interactions During Neural Crest Formation
$398,369Martin Ignacio Garcia-Castro · Yale University · R01 · FY2009 · DE
A mouse model for human gastrointestinal stromal tumor
$398,292Peter Besmer · Sloan-Kettering Inst Can Research · R01 · FY2011 · CA
Unraveling the Connection: How Metabolism Shapes Mammalian Persister Survival
$398,282Mehmet A. Orman · University Of Houston · R01 · FY2025 · CA
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
$398,271Ryan J Sullivan · Massachusetts General Hospital · R01 · FY2018 · CA
Development of a small-molecule immunomodulator for the treatment of melanoma
$398,242Rukiyah Van Dross · Claradele Pharmaceuticals, Inc. · R41 · FY2022 · CA
Anti-angiogenesis targeted vaccine therapy
$398,219Samir Khleif · Basic Sciences · Z01 · FY2007 · CA